Vinorelbine and Topotecan for Lung Cancer
Author Information
Author(s): Beldner Matthew A, Sherman Carol A, Green Mark R, Garrett-Mayer Elizabeth, Chaudhary Uzair, Meyer Mario L, Kraft Andrew S, Montero Alberto J
Primary Institution: Medical University of South Carolina
Hypothesis
The study aims to evaluate the optimal dosage and the maximal tolerated dose (MTD) of topotecan and vinorelbine in patients with relapsed or refractory non-small cell or small cell lung cancer.
Conclusion
Vinorelbine and topotecan administered on days 1 and 8 every 21 days is well tolerated and provides a potentially active non-platinum containing doublet for the treatment of advanced lung cancer.
Supporting Evidence
- The MTD was not reached in any of the 5 cohorts.
- One patient had a partial response with four patients (27%) achieving stable disease.
- The median progression-free survival for all patients was 2.7 months.
- The median overall survival for all patients was 10.5 months.
Takeaway
Doctors tested a new combination of two cancer drugs to see if they could help patients with lung cancer without causing too many side effects.
Methodology
Eighteen patients with advanced or recurrent NSCLC or SCLC were enrolled and treated with vinorelbine and escalating doses of topotecan on days 1 and 8 every 21 days.
Limitations
The study had a small sample size and was conducted at a single center.
Participant Demographics
Patients were predominantly male and female, aged 49 to 77, with a median age of 64, and most had received multiple prior lines of chemotherapy.
Statistical Information
Confidence Interval
{"progression_free_survival":"95% CI: 1.6, 9.1","overall_survival":"95% CI: 4.2, 22.7"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website